Increased urothelial cell detection in the primary bladder smooth muscle cell cultures with dual MACS/qRT-PCR approach

Applied Immunohistochemistry and Molecular Morphology

Volumn 19, Issue 2, 2011, Pages 184-189

  W Genheimer, Chistopher ^a   Guthrie, Kelly I ^a   Shokes, Jacob E ^a   Bruce, Andrew T ^a   Quinlan, Sarah F ^a   Sangha, Namrata ^a   M Ilagan, Roger ^a   Basu, Joydeep ^a   Burnette, Teresa ^a   Ludlow, John W ^a  

^a Tengion Inc   (United States)

Author keywords

Bladder; cancer; CD326; cell sorting; detection assays; regenerative medicine; smooth muscle cell; urothelium

Indexed keywords

CYTOKERATIN 5; EPITHELIAL CELL ADHESION MOLECULE;

ARTICLE; BLADDER; CELL CULTURE; CELL POPULATION; CELL SELECTION; CELL TYPE; DIAGNOSIS, MEASUREMENT AND ANALYSIS; HUMAN; HUMAN CELL; LABORATORY TEST; MAGNETIC ACTIVATED CELL SORTING; NEOPLASM; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; STOMACH MUSCLE; UPREGULATION; UROTHELIUM;

ANIMALS; ANTIGENS, NEOPLASM; CARCINOMA, TRANSITIONAL CELL; CELL ADHESION MOLECULES; CELL CULTURE TECHNIQUES; FLOW CYTOMETRY; HUMANS; KERATIN-5; MAGNETICS; MYOCYTES, SMOOTH MUSCLE; ORGAN CULTURE TECHNIQUES; REGENERATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE ENGINEERING; TISSUE SCAFFOLDS; TRANSPLANTATION, AUTOLOGOUS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; URINARY BLADDER, NEUROGENIC; UROTHELIUM;

EID: 79951953894     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181f09311     Document Type: Article

References (41)

1. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer. 2005;5:713-725.
2. American Cancer Society. How many people get bladder cancer? May 6. Available at: http://www.cancer.org/docroot/CRI/content/ CRI-2-2-1X-How-many- people-get-bladder-cancer-44.asp. Accessed March 17, 2010.
3. National Cancer Institute. Bladder cancer. Available at: http:// www.cancer.gov/cancertopics/types/bladder. AccessedMarch 17, 2010.
4. Konety BR, Joyce GF, Wise M. Bladder and upper tract urothelial cancer. J Urol. 2007;177:1636-1645. (Pubitemid 46560679)
5. Scales CD, Leonardy J, Curtis LH, et al. Trends in urinary diversion following radical cystectomy in the united states. J Urol. 2008;179:244.
6. Atala A, Bauer SB, Soker S, et al. Tissue-engineered autologous bladders for patients needing cystoplasty. Lancet. 2006;367:1241-1246.
7. De Filippo RE, Bertram TA, Jayo MJ, et al. Adaptive regulation of regenerated bladder size after implantation with tengion neobladder augment: early clinical outcomes and preclinical evidence. J Urol. 2009;181:267.
8. Jayo MJ, Jain D, Ludlow JW, et al. Long-term durability, tissue regeneration and neo-organ growth during skeletal maturation with a neo-bladder augmentation construct. Regen Med. 2008;3:671-682.
9. Jayo MJ, Jain D, Wagner BJ, et al. Early cellular and stromal responses in the regeneration of a functional mammalian bladder. J Urol. 2008;180:392-397.
10. Oberpenning F, Meng J, Yoo JJ, et al. De novo reconstitution of a functional mammalian urinary bladder by tissue engineering. Nat Biotechnol. 1999;17:149-155. (Pubitemid 29072538)
11. Seltzer E, Tillinger M, Jayo MJ, et al. Role of biomechanical stimulation (cycling) in neo-bladder regeneration-translational basis for clinical outcomes. J Urol. 2009;181:282.
12. Bertram TA, Christ GJ, Aboushwareb T, et al. Total regenerated urinary bladders are structurally and pharmacologically similar to native canine bladder tissue. J Urol. 2008;179(4, suppl 1):76.
13. Bertram TA, Christ GJ, Andersson KE, et al. Pharmacologic response of regenerated bladders in a preclinical model. FASEB J. 2009;23:291.
14. Naoe M, Ogawa Y, Morita J, et al. Detection of circulating urothelial cancer cells in the blood using the cellsearch system. Cancer. 2007;109:1439-1445. (Pubitemid 46466573)
15. Leone F, Perissinotto E, Viale A, et al. Detection of breast cancer cell contamination in leukapheresis product by real-time quantitative polymerase chain reaction. Bone Marrow Transplant. 2001;27:517-523. (Pubitemid 32266502)
16. Kraeft SK, Sutherland R, Gravelin L, et al. Detection and analysis of cancer cells in blood and bone marrow using a rare event imaging system. Clin Cancer Res. 2000;6:434-442. (Pubitemid 30111461)
17. Franklin WA, Glaspy J, Pflaumer SM, et al. Incidence of tumor-cell contamination in leukapheresis products of breast cancer patients mobilized with stem cell factor and granulocyte colony-stimulating factor (g-csf) or with g-csf alone. Blood. 1999;94:340-347. (Pubitemid 29300167)
18. Pantel K, Schlimok G, Angstwurm M, et al. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother. 1994;3:165-173.
19. Brugger W, Bross KJ, Glatt M, et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood. 1994;83:636-640. (Pubitemid 24043720)
20. Ross AA, Cooper BW, Lazarus HM, et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood. 1993;82:2605-2610. (Pubitemid 23318065)
21. Osborne MP, Wong GY, Asina S, et al. Sensitivity of immunocytochemical detection of breast cancer cells in human bone marrow. Cancer Res. 1991;51:2706-2709.
22. Litvinov SV, Velders MP, Bakker HA, et al. Ep-cam: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol. 1994;125:437-446. (Pubitemid 24135956)
23. Brunner A, Prelog M, Verdorfer I, et al. Epcam is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder. J Clin Pathol. 2008;61:307-310. (Pubitemid 351354235)
24. Moldenhauer G, Momburg F, Moller P, et al. Epithelium-specific surface glycoprotein of mr 34,000 is a widely distributed human carcinoma marker. Br J Cancer. 1987;56:714-721. (Pubitemid 18048339)
25. Trzpis M, McLaughlin PM, de Leij LM, et al. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol. 2007;171:386-395. (Pubitemid 47344671)
26. Kim BS, Atala A. Mesenchymal cell culture: Smooth muscle. In: Atala A, Lanza RP, eds. Methods of tissue engineering. San Diego, CA: Academic Press; 2002:287-292.
27. Lai JY, Atala A. Epithelial cell culture: Urothelium. In: Atala A, Lanza RP, eds. Methods of tissue engineering. San Diego, CA: Academic Press; 2002:243-246.
28. Garrel R, Dromard M, Costes V, et al. The diagnostic accuracy of reverse transcription-pcr quantification of cytokeratin mrna in the detection of sentinel lymph node invasion in oral and oropharyngeal squamous cell carcinoma: a comparison with immunohistochemistry. Clin Cancer Res. 2006;12:2498-2505.
29. Kaufmann O, Fietze E, Mengs J, et al. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol. 2001;116:823-830. (Pubitemid 33108152)
30. Yang YC, Li X, Chen W. Characterization of genes associated with different phenotypes of human bladder cancer cells. Acta Biochim Biophys Sin (Shanghai). 2006;38:602-610. (Pubitemid 44395194)
31. Noguchi S, Aihara T, Motomura K, et al. Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase- polymerase chain reaction. Comparison between muc1 mrna and keratin 19 mrna amplification. Am J Pathol. 1996; 148:649-656. (Pubitemid 26056749)
32. Buchumensky V, Klein A, Zemer R, et al. Cytokeratin 20: a new marker for early detection of bladder cell carcinoma? J Urol. 1998;160:1971-1974. (Pubitemid 128703594)
33. Gudemann CJ, Weitz J, Kienle P, et al. Detection of hematogenous micrometastasis in patients with transitional cell carcinoma. J Urol. 2000;164:532-536. (Pubitemid 30481979)
34. Wu X, Kakehi Y, Zeng Y, et al. Uroplakin ii as a promising marker for molecular diagnosis of nodal metastases from bladder cancer: comparison with cytokeratin 20. J Urol. 2005;174: 2138-2142. (Pubitemid 41611755)
35. Yin H, He Q, Li T, et al. Cytokeratin 20 and ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium. Appl Immunohistochem Mol Morphol. 2006;14:260-265. (Pubitemid 44319050)
36. Radbruch A, ed. Flow cytometry and cell sorting. 2nd ed. Berlin: Springer-Verlag; 1999.
37. Elsamman E, Fukumori T, Ewis AA, et al. Differences in gene expression between noninvasive and invasive transitional cell carcinoma of the human bladder using complementary deoxyribonucleic acid microarray: preliminary results. Urol Oncol. 2006;24:109-115. (Pubitemid 43348356)
38. Fogh J. Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors. Natl Cancer Inst Monogr. 1978;49:5-9. (Pubitemid 9152616)
39. Joseph D, Borer J, De Filippo R, et al. A phase 2 study-autologous neobladder construct (nbc) for augmentation cystoplasty in subjects with neurogenic bladder secondary to spina bifida. J Urol. 2009;181:555-556.
40. Swansbury J, ed. Cancer cytogenetics: Methods and protocols. Totowa, NJ: Humana Press; 2003.
41. Barch MJ, Knutsen T, Spurbeck JL, eds. The agt cytogenetics laboratory manual. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 1997.